These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 26329437)

  • 1. Dopaminergic Therapy for Restless Legs Syndrome/Willis-Ekbom Disease.
    Zak RS; Walters AS
    Sleep Med Clin; 2015 Sep; 10(3):279-85, xiii. PubMed ID: 26329437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation.
    Garcia-Borreguero D; Silber MH; Winkelman JW; Högl B; Bainbridge J; Buchfuhrer M; Hadjigeorgiou G; Inoue Y; Manconi M; Oertel W; Ondo W; Winkelmann J; Allen RP
    Sleep Med; 2016 May; 21():1-11. PubMed ID: 27448465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopaminergic Augmentation in Restless Legs Syndrome/Willis-Ekbom Disease: Identification and Management.
    García-Borreguero D
    Sleep Med Clin; 2015 Sep; 10(3):287-92, xiii. PubMed ID: 26329438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restless legs syndrome/Willis Ekbom disease: evaluation and treatment.
    Allen RP
    Int Rev Psychiatry; 2014 Apr; 26(2):248-62. PubMed ID: 24892899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Augmentation of restless leg syndrome (Willis-Ekbom disease) during long-term dopaminergic treatment.
    Garcia-Borreguero D; Benitez A; Kohnen R; Allen R
    Postgrad Med; 2015; 127(7):716-25. PubMed ID: 26077324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What treatment works best for restless legs syndrome? Meta-analyses of dopaminergic and non-dopaminergic medications.
    Hornyak M; Scholz H; Kohnen R; Bengel J; Kassubek J; Trenkwalder C
    Sleep Med Rev; 2014 Apr; 18(2):153-64. PubMed ID: 23746768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome.
    Silver N; Allen RP; Senerth J; Earley CJ
    Sleep Med; 2011 May; 12(5):440-4. PubMed ID: 21239226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ropinirole in restless leg syndrome.
    Ahmed I
    Mo Med; 2002; 99(9):500-1. PubMed ID: 12462942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on the treatment of Restless Legs Syndrome/Willis-Ekbom Disease: prospects and challenges.
    Zucconi M; Galbiati A; Rinaldi F; Casoni F; Ferini-Strambi L
    Expert Rev Neurother; 2018 Sep; 18(9):705-713. PubMed ID: 30095315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists.
    Tippmann-Peikert M; Park JG; Boeve BF; Shepard JW; Silber MH
    Neurology; 2007 Jan; 68(4):301-3. PubMed ID: 17242339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. D3 receptor agonist efficacy in restless legs syndrome.
    Casoni F; Galbiati A; Ferini-Strambi L
    Adv Pharmacol; 2019; 84():21-35. PubMed ID: 31229173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targinact for restless legs syndrome.
    Drug Ther Bull; 2016 Apr; 54(4):42-5. PubMed ID: 27079737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 'Restless bladder' and the boundaries of the restless legs syndrome.
    Antelmi E; Coccagna G; Ferini-Strambi L; Marelli S; Provini F
    Eur J Neurol; 2013 Nov; 20(11):e128. PubMed ID: 24118170
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of α2δ Ligands for Restless Legs Syndrome/Willis Ekbom Disease.
    Faulkner MA
    CNS Drugs; 2018 Feb; 32(2):149-159. PubMed ID: 29480463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ropinirole in the treatment of restless legs syndrome.
    Kakar RS; Kushida CA
    Expert Rev Neurother; 2005 Jan; 5(1):35-42. PubMed ID: 15853472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine agonists for the treatment of restless legs syndrome.
    Fulda S; Wetter TC
    Expert Opin Pharmacother; 2005 Dec; 6(15):2655-66. PubMed ID: 16316304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ropinirole: new indication. Restless legs: disproportionate adverse effects.
    Prescrire Int; 2006 Oct; 15(85):173-6. PubMed ID: 17128523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute.
    García-Borreguero D; Allen RP; Kohnen R; Högl B; Trenkwalder C; Oertel W; Hening WA; Paulus W; Rye D; Walters A; Winkelmann J; Earley CJ;
    Sleep Med; 2007 Aug; 8(5):520-30. PubMed ID: 17544323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of dopamine agonists in restless legs syndrome.
    Hornyak M; Trenkwalder C; Kohnen R; Scholz H
    Sleep Med; 2012 Mar; 13(3):228-36. PubMed ID: 22281001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with pramipexole in the treatment of restless legs syndrome.
    Merlino G; Serafini A; Robiony F; Valente M; Gigli GL
    Expert Opin Drug Metab Toxicol; 2008 Feb; 4(2):225-35. PubMed ID: 18248314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.